Table 2.
PMT inhibitors that have advanced to study in human clinical trials.
| compound | target | clinical indication | status | Clinicaltrials.gov identifier |
|---|---|---|---|---|
| pinometostat (EPZ-5676) | D0T1 L | adults with relapsed/refractory MLL-r leukaemia | phase 1 | NCT01684150 |
| pinometostat (EPZ-5676) | D0T1 L | Paediatric patients with relapsed/refractory MLL-r leukaemia | phase 1 | NCT02141828 |
| tazemetostat (EPZ-6438) | EZH2 | non-Hodgkin's lymphoma | phase 2 | NCT01897571 |
| tazemetostat (EPZ-6438) | EZH2 | adults with INI1-negative tumours or relapsed/refractory synovial sarcoma | phase 2 | NCT02601950 |
| tazemetostat (EPZ-6438) | EZH2 | Paediatric subjects with relapsed or refractory INI1-negative tumours or synovial sarcoma | phase 1 | NCT02601937 |
| tazemetostat (EPZ-6438) | EZH2 | malignant mesothelioma | phase 2 | NCT02860286 |
| Tazemetostat (EPZ-6438)/atezolizumab combination | EZH2 + PD-L1 | diffuse large B-cell lymphoma | phase 1 | NCT02220842 |
| tazemetostat (EPZ-6438)/R-CHOP | EZH2 + various targets | diffuse large B-cell lymphoma | phase 1b/2 | NCT02889523 |
| GSK2816126 | EZH2 | non-Hodgkin's lymphoma, solid tumours and multiple myeloma | phase 1 | NCT02082977 |
| CPI-1205 | EZH2 | B-cell lymphomas | phase 1 | NCT02395601 |
| DS-3201b | EZH2/EZH1 | non-Hodgkin's lymphoma | phase 1 | NCT02732275 |
| MAK683 | PRC2 complex disruption | adult patients with advanced malignancies | phase 1 | NCT02900651 |
| EPZ015938/GSK3326595 | PRMT5 | Solid tumours and non-Hodgkin's lymphoma | phase 1 | NCT02783300 |